Centre Hospitalier Lyon Sud ( Site 3102)

Pierre-Bénite, Rhone 69495

0 studies enrolling now · 1 studies all time

What they study most

Melanoma

Studies at this site

• Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02) — Completed